Cisco (CSCO) dips on seventh straight quarterly sales decline >>> READ MORE

5 Stocks Leading the Generic Drug Charge

Between legislation and a wave of patent expiration, these pharmaceuticals are sitting pretty

      View All  

Doctor Reddy’s

Dr Reddy 185Doctor Reddy’s (RDY) is often one of generic drug industry’s forgotten names, possibly because it’s only a $6.4 billion outfit, or possibly because most consumers would struggle to name one generic drug the company actually makes.

Size is all relative to sales and profits, however, and on that front, Doctor Reddy’s is a growth machine. Revenue has improved an average of 25% for the past couple of fiscal years, and profit growth has been commensurate. The decision to shift away from generics and towards self-developed branded drugs is seen by some as a liability, but could just as easily be deemed an opportunity to complement its existing generic business.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC